The Predictive Value of Coexisting TMPRSS2-ERG Gene Fusion and PTEN Deletion in Prostate Cancer Patients with Biochemical Failure Status Post Salvage or Radical Radiation Therapy

What this study is about

The objective of the study is to evaluate the predictive value of TMPRSS2-ERG gene fusion and PTEN in patients with high risk prostate cancer treated with first line LHRH agonist after biochemical failure.

Who can join (things the study team will check)

✅ You may be able to join if…

• T3a +
• PSA > 20
• Gleason 8 or higher
• Karnofsky performance status ≥ 70.
• Signed study-specific informed consent

Where this trial is running

• CIUSSS du Saguenay-Lac-St-Jean/CSSS de Chicoutimi, Chicoutimi, Quebec, Canada
• CISSS de la Montérégie-Centre - Hôpital Charles-LeMoyne, Greenfield Park, Quebec, Canada
• CISSS de Laval - Hôpital de la Cité-de-la-santé de Laval, Laval, Quebec, Canada
• CIUSSS de l'Est-de-l'Île-de-Montréal - Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada
• Jewish General Hospital, McGill University, Montreal, Quebec, Canada
• MUHC - Cedars Cancer Center, Montreal, Quebec, Canada
• CHU - L'Hôtel-Dieu de Québec, Québec, Quebec, Canada
• CIUSSS de l'Estrie - Hôpital Fleurimont, Sherbrooke, Quebec, Canada
• CIUSSS de la Mauricie-et-du-centre-du Quebec - Centre hospitalier régional de Trois-Rivières, Trois-Rivières, Quebec, Canada

Who to contact

Ashley Feng, M.Sc. · 514-340-8222 · yanqi.feng.ccomtl@ssss.gouv.qc.ca

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT02573636.